FAMOTIDINE IV INJECTION 10 MG — DIN 02247800
FAMOTIDINE : 10 MG · TEVA CANADA LIMITED · SOLUTION · wholesale supply in Canada
Health Canada status: CANCELLED PRE MARKET
What is FAMOTIDINE IV INJECTION?
FAMOTIDINE IV INJECTION 10 MG contains FAMOTIDINE : 10 MG. It is listed in the Health Canada Drug Product Database under DIN 02247800, held by TEVA CANADA LIMITED, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as cancelled pre market, status dated 16-Oct-2015. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
What is FAMOTIDINE IV INJECTION used for?
Acute duodenal/benign gastric ulcer; prophylaxis of duodenal ulcer; pathological hypersecretory conditions (e.g. Zollinger-Ellison); GERD; maintenance of remission of GERD.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Famotidine cost around the world?
Famotidine is listed on 11 of the national price registers Nexara ingests. Each country publishes on a different basis, so figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Austria publishes a KVP (Kassenverkaufspreis); Bahrain publishes a retail (max). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed |
|---|---|---|---|
| United States | acquisition | 5 | 112 |
| Saudi Arabia | public | 11 | 21 |
| Austria | KVP (Kassenverkaufspreis) | 9 | 18 |
| Czechia | max producer price (ex-factory) | 2 | 7 |
| Bahrain | retail (max) | 3 | 6 |
| Greece | producer price (ex-factory) | 6 | 6 |
| Australia | ex-manufacturer | 2 | 4 |
| Morocco | PPV (public price) | 3 | 4 |
| United Arab Emirates | public | 2 | 2 |
| United Kingdom | hospital | 2 | 2 |
| Iceland | max wholesale | 2 | 2 |
184 pack listings across 47 brand entries and 10 price bases, refreshed 10 Sep 2026. Ranges span every Famotidine pack in that market, so a high figure is usually a larger pack rather than the same product.
This table is a regulatory record of where the molecule is listed. The DIN on this page is no longer authorized for sale in Canada, so Nexara does not quote it — see the alternatives above.
Is there a generic Famotidine in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
27 holders have a Canadian DIN containing Famotidine, across 68 DINs, of which 17 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| ANGITA PHARMA INC. | 3 | 3 | ACID CONTROLLER MAXIMUM STRENGTH, AG-FAMOTIDINE | Sourceable in Canada |
| TEVA CANADA LIMITED | 8 | 2 | ACID CONTROL, FAMOTIDINE (ACID CONTROLLER) TABLETS, FAMOTIDINE IV INJECTION, NTP-FAMOTIDINE, TEVA-FAMOTIDINE | Sourceable in Canada |
| MCNEIL CONSUMER HEALTHCARE DIVISION OF JOHNSON & JOHNSON INC | 3 | 2 | MAXIMUM STRENGTH PEPCID AC, PEPCID AC | Sourceable in Canada |
| JAMP PHARMA CORPORATION | 2 | 2 | JAMP FAMOTIDINE | Sourceable in Canada |
| MINT PHARMACEUTICALS INC | 2 | 2 | MINT-FAMOTIDINE | Sourceable in Canada |
| OMEGA LABORATORIES LIMITED | 2 | 2 | FAMOTIDINE OMEGA -(WITH PRESERVATIVE,BENZYL ALCOHOL), FAMOTIDINE OMEGA -(WITHOUT PRESERVATIVE) | Sourceable in Canada |
| SANIS HEALTH INC | 2 | 2 | FAMOTIDINE | Sourceable in Canada |
| SIVEM PHARMACEUTICALS ULC | 2 | 2 | FAMOTIDINE | Sourceable in Canada |
| APOTEX INC | 8 | 0 | ACID CONTROL, APO-FAMOTIDINE, APO-FAMOTIDINE INJECTABLE, APO-FAMOTIDINE TAB 20MG USP, APO-FAMOTIDINE TAB 40MG USP, +1 more | No marketed DIN |
| MYLAN PHARMACEUTICALS ULC | 5 | 0 | FAMOTIDINE INJECTION, MYLAN-FAMOTIDINE, PEPTIC GUARD | No marketed DIN |
| MERCK CANADA INC | 4 | 0 | PEPCID AC (CHEWABLE TAB) - 10MG, PEPCID I.V. 10MG/ML, PEPCID TAB 20MG, PEPCID TAB 40MG | No marketed DIN |
| AURO PHARMA INC | 3 | 0 | AURO-FAMOTIDINE 10 MG, AURO-FAMOTIDINE 20 MG, AURO-FAMOTIDINE MINT 20 MG | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 10 MG |
|---|---|
| Dosage form | SOLUTION |
| Route | INTRAVENOUS |
| Pack configuration (monograph) | Tablets: Bottles of 100, 500; unit dose 30, 100. Injection: 2 mL single-use vials; 4 mL, 20 mL multidose vials; 50 mL Pharmacy Bulk vials. |
| Storage | Tablets: 15-30°C, light-resistant. Injection: 2°C to 8°C, protect from light, do not freeze. Diluted IV solution: use within 24 hours. |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Famotidine |
|---|---|
| ATC code | A02BA03 |
| AHFS class | 56:28.12 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02247800 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2247800 |
| Brand name | FAMOTIDINE IV INJECTION |
| Generic / active ingredient | FAMOTIDINE : 10 MG |
| Market authorization holder | TEVA CANADA LIMITED |
| Health Canada schedule | Prescription |
| ATC code | A02BA03 |
| ATC anatomical main group | A — Alimentary tract and metabolism |
| ATC therapeutic subgroup | A02BA |
| Current status | CANCELLED PRE MARKET |
| Status date | 16-Oct-2015 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Duodenal/Gastric Ulcer: 40 mg at bedtime. GERD: 20-40 mg twice daily. IV: 20 mg every 12 hours. Adjust dose in moderate/severe renal insufficiency (reduce dose by half or extend interval to 36-48h).
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity to famotidine or any component of the medication. Cross-sensitivity with other H2-receptor antagonists has been observed.
Warnings and precautions
Exclude gastric malignancy before treating gastric ulcers. CNS adverse effects reported in patients with moderate to severe renal insufficiency. Contains benzyl alcohol (multidose vials).
Is Famotidine in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Active — reported by OMEGA LABORATORIES LIMITED (Tier 3 shortage FAMOTIDINE OMEGA -(WITHOUT PRESERVATIVE)" aria-label="Actual Tier 3 shortage FAMOTIDINE OMEGA -(WITHOUT), last seen 09 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
17 of 68 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACID CONTROLLER MAXIMUM STRENGTH | 20 MG | TABLET | ANGITA PHARMA INC. | MARKETED | 02538350 |
| AG-FAMOTIDINE | 20 MG | TABLET | ANGITA PHARMA INC. | MARKETED | 02509970 |
| AG-FAMOTIDINE | 40 MG | TABLET | ANGITA PHARMA INC. | MARKETED | 02509989 |
| FAMOTIDINE | 40 MG | TABLET | SIVEM PHARMACEUTICALS ULC | MARKETED | 02549115 |
| FAMOTIDINE | 40 MG | TABLET | SANIS HEALTH INC | MARKETED | 02351110 |
| FAMOTIDINE | 20 MG | TABLET | SANIS HEALTH INC | MARKETED | 02351102 |
| FAMOTIDINE | 20 MG | TABLET | SIVEM PHARMACEUTICALS ULC | MARKETED | 02549107 |
| FAMOTIDINE OMEGA -(WITH PRESERVATIVE,BENZYL ALCOHOL) | 10 MG | SOLUTION | OMEGA LABORATORIES LIMITED | MARKETED | 02247745 |
| FAMOTIDINE OMEGA -(WITHOUT PRESERVATIVE) | 10 MG | SOLUTION | OMEGA LABORATORIES LIMITED | MARKETED | 02247735 |
| JAMP FAMOTIDINE | 40 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | 02507757 |
2 · Same class — other molecules in ATC A02BA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Famotidine | ACID CONTROL · ACID CONTROLLER MAXIMUM STRENGTH · ACT · AG-FAMOTIDINE · +39 more | 68 | 17 | Yes |
| Ranitidine | ACID REDUCER · ACID REDUCER MAXIMUM STRENGTH NON-PRESCRIPTION · ACT RANITIDINE · AG-RANITIDINE · +46 more | 96 | 5 | Yes |
| Cimetidine | APO-CIMETIDINE ORAL SOLUTION · CIMETIDINE · CIMETIDINE 200 TAB 200MG · CIMETIDINE TAB 300MG · +27 more | 50 | 2 | Yes |
| Nizatidine | APO-NIZATIDINE · AXID · DOM-NIZATIDINE 150MG CAPSULES · GEN-NIZATIDINE · +7 more | 19 | 1 | Yes |
| Famotidine, Combinations | PEPCID COMPLETE | 1 | 1 | Yes |
| Ranitidine Bismuth Citrate | PYLORID | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC A02B
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| A02BC | Dexlansoprazole · Esomeprazole · Lansoprazole · Omeprazole · Pantoprazole · +1 more | 288 | 108 |
| A02BX | Alginic Acid · Pirenzepine · Sucralfate | 32 | 4 |
| A02BB | Misoprostol | 10 | 2 |
| A02BD | Bismuth Subcitrate,Tetracycline And Metronidazole · Lansoprazole, Amoxicillin And Clarithromycin | 3 | 2 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is FAMOTIDINE IV INJECTION called?
The same molecule, Famotidine, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| FAMOSAN | Latin | Czechia |
| famodar | Latin | Bahrain, Saudi Arabia |
| Famotidine Amarox | Latin | Saudi Arabia |
| FAMOGEN | Latin | Saudi Arabia |
| FAMOPSIN | Latin | Bahrain |
| ULCERAN | Latin | Bahrain |
| Famodine | Latin | Saudi Arabia |
| Famotidin Genericon | Latin | Iceland |
| Famotidin STADA | Latin | Iceland |
| Famotidine for oral suspension | Latin | Saudi Arabia |
| QUAMATEL | Latin | Czechia |
| ULCIDINE | Latin | Morocco |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
What is Famotidine called in other languages?
Buyers, prescribers and procurement teams outside Canada often search for the ingredient in their own script. These are phonetic renderings of the ingredient name Famotidine, published to help those searches reach this page.
| Language | Famotidine |
|---|---|
| Arabic العربية | فاموتيدين |
| Chinese (Simplified) 简体中文 | 法莫替丁 |
| Russian Русский | фамотидин |
| Spanish Español | famotidina |
| French Français | famotidine |
| Portuguese Português | famotidina |
| German Deutsch | Famotidin |
| Persian فارسی | فاموتیدین |
| Turkish Türkçe | famotidin |
| Japanese 日本語 | ファモチジン |
| Thai ไทย | ฟาโมทิดีน |
| Indonesian Bahasa Indonesia | famotidin |
| Hebrew עברית | פמוטידין |
| Italian Italiano | famotidina |
These are transliterations of the ingredient name, generated automatically and published only where two independent checks agreed. They are not registered local trade names and carry no marketing authorisation in any market. Always confirm a product against its local registration before ordering.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled pre market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.